Tag: precision medicine

19
Aug 2019

Bionest

Applying Precision Medicine to Neuropsychiatric Disorders

Cancers were once looked upon as specific diseases, often defined by their tissue of origin, and drug treatments primarily aimed to kill rapidly growing tumor cells before harming slower growing normal ones. The result was often limited drug efficacy, accompanied by debilitating side-effects. Today, however, the growing understanding of the biology and genetics of particular...
30
May 2019

Bionest

Meet You at ASCO!

ASCO, the world’s largest meeting focused on cancer, is always one of the highlights of our calendar here at Bionest. This year is no exception and several of us are headed to Chicago for this year’s event, which is being held from May 31 to June 4. If you are going to ASCO, we’d love...
28
May 2019

Bionest

Join Us at BIO for “Precision Medicine Beyond Oncology”

The original vision of “personalized medicine” focused on tailoring medications to the biology of the individual patient — treating them with the right drug at the right time. That view has since evolved beyond therapy selection to increasingly encompass aspects of drug discovery, planning and delivery of care, and patient engagement. This new approach, now...
20
Nov 2018

Bionest

“All of Us” Achieves Substantial Recruitment Milestone in Record Time

In 2015, the U.S. National Institutes of Health (NIH) announced plans for a major precision medicine initiative. The program is designed to take into account individual differences in lifestyle, environment and biology by gathering health data over time from more than a million people across the country. Its ultimate goal is to accelerate medical research and...
10
Jul 2018

Bionest

Precision Medicine and NGS Cancer Panels — ASCO Round-Up Part Two

As we wrote in our last post, precision medicine in oncology was the big theme of this year’s ASCO meeting. One of the key advances that has made possible this focus on treating cancer based on particular biomarkers expressed by a patient’s tumors, has been the advent of Next-Generation Sequencing (NGS)-based analysis of tumor DNA....
31
Jan 2018

Bionest

New Large-Scale Genomic/Health Data Effort Launched, with More to Come

A recently announced six-member consortium of pharmaceutical companies is planning to turn the UK Biobank into the world’s largest publicly accessible concentration of genetic and health data. The effort is being led by Regeneron, which will perform the work at its Tarrytown, NY facility, one of the world’s largest and most sophisticated human genetics sequencing...